Biologic Imaging Reagents: Technologies and Global Markets

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biologic Imaging Reagents: Technologies and Global Markets

http://www.reportlinker.com/p099465/Biologic-Imaging-Reagents-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

STUDY GOALS AND OBJECTIVES

BCC's goal for this study was to determine the global market and future demand growth for biologic imaging reagents over a five-year period from 2012 to 2017. Our particular interest is to characterize and quantify the biologic imaging reagents market potential by technology, reagent type and end user market. We also evaluate future growth opportunities in emerging biologic imaging reagents including quantum dots, nanoparticles, fluorescent proteins and supermolecules.Imaging reagent types covered include fluorescent probes and dyes; fluorescent proteins; nanoparticles; magnetic resonance imaging, ultrasound and X-ray contrast reagents; and imaging radiopharmaceuticals.Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biologic imaging reagents and forecast the future commercial potential for the key market segments. This discussion will provide a basis for companies to make strategic choices about developing new products and markets, or employing biologic imaging reagents. The study will benefit reagent and instrument manufacturers, users of biologic imaging reagents, medical instrument companies, life sciences tools companies, diagnostic and drug manufacturers, biotechnology companies, and developers of nanotechnologies.

REASONS FOR DOING THE STUDY

Biologic imaging reagents play an important role in the medical, pharmaceutical, diagnostic, biotechnology and life sciences tools industries. Imaging and detection technologies are used extensively in medicine, biotechnology and pharmaceutical research. Traditional imaging techniques, such as X-ray, computer tomography (CT), ultrasound (US), magnetic resonance imaging (MRI) and nuclear medicine (NM), mainly analyze anatomy and morphology and cannot detect changes at the molecular level. However, new developments in biotechnology allow us to image at the cellular and molecular level, paving the way for earlier diagnosis and treatment of disease. Biologic imaging reagents play a critical role in this medical revolution.At the same time, ongoing advances in genomics, proteomics and cellular analysis are aided by imaging technologies, including fluorescent dyes and probes, quantum dot nanoparticles, and fluorescent proteins. Growth in technologies such as biochips, DNA sequencing and polymerase chain reaction (PCR) relies on sensitive biologic fluorescent imaging reagents.Advances in technologies that are used in biologic imaging reagents are also moving forward at a rapid pace. These technologies include nanotechnology, biologic targeting, microfluidics, supramolecular chemistry and protein engineering. Rapid developments across a number of technology fields promise to change the biologic imaging industry by enabling novel imaging reagents and unique market opportunities. This report analyzes these developments and their impact on the future markets for biologic imaging reagents.Given these market and technology dynamics, it is especially timely to examine the biologic imaging reagents market.

CONTRIBUTION OF THE STUDY AND FOR WHOM

We have compiled a study of existing and future imaging reagent technologies that will be commercially important in the major end user segments, including life science research tools, drug discovery and development, and diagnostics.We present the various imaging reagent technologies, including fluorescent probes and dyes, nanomaterials, fluorescent proteins, contrast reagents, and imaging radiopharmaceuticals. We also examine the industry growth driving forces; product types; market applications; companies and industry alliances and acquisitions; future market potential; and product sales forecasts for the period 2012 through 2017. We project the future use of biologic imaging reagents in the main end user segments and by technology.This study will be of particular interest to life science research tools suppliers, pharmaceutical manufacturers, diagnostics, biotechnology, genomics, proteomics, nanotechnology and supramolecular companies. It will also be of interest to companies making products for medical imaging, microarrays, lab on a chip, polymerase chain reaction, molecular diagnostics assays, cell-based assays, and fluorescence activated cell sorting (FACS) as well as medical researchers and clinicians.

SCOPE AND FORMAT

The study scope includes the biologic imaging reagents that are commercial or likely to be commercialized within the next five years. Fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals are studied. Both the in-vivo and in-vitro market segments are included. Each technology is analyzed to determine its market status, impact on future market segments and forecasted growth from 2012 through 2017. Technology status and market driving forces are also discussed.BCC examines imaging reagent producers and the industry structure in specialized segments of the industry. We also review industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and research and development (R&D) tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis. The markets for novel biologic imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents, are analyzed, and the main companies in these fields are highlighted.

METHODOLOGY

BCC talked to key users and producers in the end user market segments and technology fields that will be commercially important during the next five years. Extensive secondary market research was performed.Based on our analysis, we project the future applications of biologic imaging reagents in the major end user market segments and by technology type and forecast sales revenues for 2012 through 2017.

INFORMATION SOURCES

BCC surveyed academic, government and industrial institutions to obtain data for this study. Included were life science research tools, pharmaceutical, diagnostic, biotechnology and nanotechnology firms, and leading life science research institutions. We also spoke with leading industry thought leaders. In addition, we compiled data from secondary sources, including industry, trade and government.

ANALYST CREDENTIALS

The author, John Bergin, has written numerous BCC biotechnology reports on genomics, microarrays, DNA sequencing, synthetic biology, epigenomics and diagnostics.Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with an emerging separations company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology and Masters of Business Administration.

REPORT HIGHLIGHTS

This report provides:- An overview of the global market for biologic imaging reagents, including those that are commercial or likely to be commercialized within the next five years- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017- Coverage of fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; supermolecules; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals- Analysis of each technology to determine its market status and impact on future market segments- Discussion of imaging reagent producers and the industry structure in specialized segments- Reviews of industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and R&D tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis- Comprehensive company profiles of major players in the industry.

TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

CONTRIBUTION OF THE STUDY AND FOR WHOM 2

SCOPE AND FORMAT 2

METHODOLOGY 2

INFORMATION SOURCES 2

RELATED BCC REPORTS 3

ANALYST CREDENTIALS 3

BCC RESEARCH ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 EXECUTIVE SUMMARY 5SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH2017 ($ MILLIONS) 5SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS,THROUGH 2017 ($ MILLIONS) 5

CHAPTER 3 OVERVIEW 9

INTRODUCTION 9

REPORT SCOPE 9

TABLE 1 SCOPE OF THIS REPORT 10

MARKET POTENTIAL 10

TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,

THROUGH 2017 ($ MILLIONS) 10

TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY END USER MARKET,

THROUGH 2017 ($ MILLIONS) 11

INDUSTRY GROWTH DRIVING FORCES 12

TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 12

LIFE CYCLE STATUS 14

TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS 14

BIOLOGIC IMAGING REAGENTS INDUSTRY 15

TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPANIES 15

CHAPTER 4 BIOLOGIC IMAGING TECHNOLOGIES 17IMAGING REAGENT TYPES 17TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES 17IN-VIVO IMAGING MODALITIES 18TABLE 8 IN-VIVO IMAGING MODALITIES 18TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES 19MOLECULAR IMAGING 20IN-VITRO IMAGING/DETECTION 21TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING 21TRENDS IN IN-VIVO IMAGING 21TABLE 11 KEY TECHNOLOGY DRIVERS FOR IN-VIVO IMAGING REAGENTS 22BIOLOGIC IMAGING REAGENTS TECHNOLOGIES 23NANOPARTICLES 23TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS 24FLUORESCENT DYES AND PROBES 25TABLE 13 FLUORESCENT DYES AND PROBES 25TABLE 14 GENERAL ADVANTAGES OF FLUORESCENCE LABELS 26TABLE 15 FLUORESCENT DYE PERFORMANCE CRITERIA 27FLUORESCENT PROTEINS 28TABLE 16 TYPES OF FLUORESCENT PROTEINS 28Genetically Engineered Fluorescent Proteins 29TABLE 17 PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES 29Engineered Fluorescent Cell Lines 30Emerging Fluorescent Protein Applications 31TABLE 18 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS 31Comparison of Fluorescent Proteins with Fluorescent Dyes 31TABLE 19 FLUORESCENT PROTEINS VERSUS DYES 32Technology Challenges 32TABLE 20 TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS 32SUPERMOLECULES 33TABLE 21 CLASSIFICATION OF IMAGING SUPERMOLECULES 33QUANTUM DOTS 34TABLE 22 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENTPROTEINS 34FIGURE 1 QUANTUM DOT SPECTRA (INTENSITY) 35FIGURE 2 FLUORESCENT DYE SPECTRA 35TABLE 23 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS 37RADIOPHARMACEUTICAL IMAGING REAGENTS 38CONTRAST IMAGING REAGENTS 38TABLE 24 MICROBUBBLE ULTRASOUND IMAGING AGENTS 40EMERGING CLASSES OF IMAGING REAGENTS 40COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 40FIGURE 3 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 41ADVANCED IMAGING REAGENT FUNCTIONS 42TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS 42Dual Modality Reagents 42Multifunctional Reagents 42Multiplexed Reagents 43BIOLOGIC IMAGING REAGENTS MANUFACTURING COSTS 43FIGURE 4 ESTIMATED MANUFACTURING COSTS OF IMAGING REAGENTS CLASSES($/GRAM) 44COMPARISON OF IMAGING REAGENT TECHNOLOGY PLATFORMS 45TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES 46TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS 47TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS 48

CHAPTER 5 BIOLOGIC IMAGING REAGENTS APPLICATIONS 50

OVERVIEW 50

TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS 50

TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND

MEDICAL INDUSTRIES 51

TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT 52

TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS 52

RESEARCH AND DEVELOPMENT 53

TABLE 33 R&D TOOLS IMAGING REAGENTS 53

TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS 54

DRUG DISCOVERY AND DEVELOPMENT 54

TABLE 35 IMAGING APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 55

INFLUENCE OF IMAGING TECHNOLOGY ON DRUG DEVELOPMENT 55

ATTRITION RATE OF LEAD DRUG COMPOUNDS 56

FIGURE 5 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT 57

FLUORESCENT PROTEIN APPLICATIONS IN DRUG DISCOVERY 57

IN-VIVO SMALL ANIMAL IMAGING APPLICATIONS 58

TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES 58

TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING 59

DIAGNOSTICS 59

INTRODUCTION 59

TABLE 38 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS 60

DIAGNOSTIC APPLICATIONS OF IMAGING REAGENTS 60

TABLE 39 DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS 61

Fluorescent Dyes, Probes and Tags 61

Nanoparticles 61

Supermolecules 62

Imaging Radiopharmaceuticals 62

Contrast Reagents 62

MOLECULAR IMAGING 63

TABLE 40 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING 63

CHAPTER 6 BIOLOGIC IMAGING REAGENTS INDUSTRY STRUCTURE 66INNOVATION WITHIN THE IMAGING REAGENT INDUSTRY 66STRATEGIC ALLIANCES 66TABLE 41 BIOLOGIC IMAGING REAGENT STRATEGIC ALLIANCES, 2010-2012 67INDUSTRY ACQUISITIONS 70TABLE 42 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2010–2012 71MEDICAL IMAGING INSTRUMENT SECTOR 72TABLE 43 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES 73FLUORESCENT DYES AND PROBES INDUSTRY STRUCTURE 73TABLE 44 FLUORESCENT IMAGING REAGENTS COMPETITORS 74QUANTUM DOTS INDUSTRY 75TABLE 45 QUANTUM DOT COMPETITORS 75CONTRAST REAGENTS INDUSTRY 76TABLE 46 CONTRAST AGENTS KEY COMPETITORS 77RADIOPHARMACEUTICALS INDUSTRY 77TABLE 47 IMAGING RADIOPHARMACEUTICALS COMPANIES 77TABLE 48 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES 79RADIOACTIVE ISOTOPES SUPPLY 80SMALL ANIMAL IN-VIVO IMAGING INDUSTRY 80TABLE 49 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING REAGENT COMPETITORS 81CARDIAC IMAGING INDUSTRY 82TABLE 50 CARDIAC IMAGING REAGENT COMPETITIVE SPACE 82PROSTATE CANCER IMAGING INDUSTRY 84TABLE 51 PROSTATE CANCER IMAGING AGENT COMPETITION 84ALZHEIMER'S DISEASE PET IMAGING INDUSTRY 85TABLE 52 ALZHEIMER'S DISEASE PET IMAGING AGENT COMPETITIVE SPACE 85

CHAPTER 7 BIOLOGIC IMAGING REAGENTS MARKETS 88

GROWTH DRIVING FORCES 88

TABLE 53 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 88

MARKET OVERVIEW 90

TABLE 54 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY APPLICATION, THROUGH

2017 ($ MILLIONS) 90

TABLE 55 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,

THROUGH 2017 ($ MILLIONS) 91

TABLE 56 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS MARKET, BY END USE,

THROUGH 2017 ($ MILLIONS) 92

TABLE 57 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET,

THROUGH 2017 ($ MILLIONS) 92

TABLE 58 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY MODALITY, THROUGH

2017 ($ MILLIONS) 93

CONTRAST REAGENTS MARKET 94

TABLE 59 GLOBAL VALUE OF CONTRAST REAGENTS MARKET, BY MODALITY, THROUGH

2017 ($ MILLIONS) 94

MRI REAGENTS MARKET 95

TABLE 60 GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE, THROUGH 2017 ($

MILLIONS) 95

TABLE 61 GLOBAL VALUE OF GD-CHELATE MRI REAGENTS BY PRODUCT, THROUGH 2017 ($

MILLIONS) 96

TABLE 62 GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, THROUGH 2017 ($

MILLIONS) 98

TABLE 63 GLOBAL SALES OF MRI CONTRAST REAGENTS BY PROCEDURE, THROUGH 2017

($ MILLIONS) 99

ULTRASOUND REAGENTS MARKET 99

TABLE 64 GLOBAL VALUE OF MICROBUBBLE ULTRASOUND REAGENTS MARKET, BY TYPE,

THROUGH 2017 ($ MILLIONS) 99

X-RAY/CT REAGENTS MARKET 100

TABLE 65 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY TYPE, THROUGH 2017 ($

MILLIONS) 101

TABLE 66 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY INDICATION, THROUGH

2017 ($ MILLIONS) 102

RADIOPHARMACEUTICALS MARKET 102

TABLE 67 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

SCANNER TYPE, THROUGH 2017 ($ MILLIONS) 102

TABLE 68 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

ISOTOPE, THROUGH 2017 ($ MILLIONS) 103

TABLE 69 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

INDICATION, THROUGH 2017 ($ MILLIONS) 104

TABLE 70 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 105

SPECT RADIOPHARMACEUTICALS MARKET 106

TABLE 71 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH

2017 ($ MILLIONS) 106

TABLE 72 HALF LIFE OF COMMON PET AND SPECT ISOTOPES 107

TABLE 73 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY INDICATION,

THROUGH 2017 ($ MILLIONS) 107

TABLE 74 SENTINEL NODE DETECTION RADIOPHARMACEUTICALS PRODUCERS 108

TABLE 75 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY TECHNOLOGY,

THROUGH 2017 ($ MILLIONS) 109

PET RADIOPHARMACEUTICALS MARKET 109

TABLE 76 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH

2017 ($ MILLIONS) 110

TABLE 77 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY INDICATION,

THROUGH 2017 ($ MILLIONS) 110

TABLE 78 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY TECHNOLOGY,

THROUGH 2017 ($ MILLIONS) 112

OPTICAL IMAGING REAGENTS MARKET 112

TABLE 79 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY

APPLICATION, THROUGH 2017 ($ MILLIONS) 112

TABLE 80 GLOBAL VALUE OF IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS

MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 113

TABLE 81 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING

REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 114

TABLE 82 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING

REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 115

TABLE 83 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT

IMAGING REAGENTS MARKET BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 116

TABLE 84 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE,

THROUGH 2017 ($ MILLIONS) 116

TABLE 85 GLOBAL VALUE OF IN-VITRO OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH

2017 ($ MILLIONS) 117

GEOGRAPHICAL MARKET 118

TABLE 86 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH

2017 ($ MILLIONS) 118

CHAPTER 8 PATENT STATUS 121IMAGING REAGENTS PATENTS BY SELECTED TECHNOLOGY 121TABLE 87 NUMBER OF PATENTS BY TECHNOLOGY, 2001-2011 121FLUORESCENCE REAGENTS 122TABLE 88 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY (NO.) 122FLUORESCENT PROTEINS 123TABLE 89 FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY (NO.) 123QUANTUM DOTS 123TABLE 90 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY (NO.) 123GOLD NANOPARTICLES 124TABLE 91 GOLD NANOPARTICLE PATENT ASSIGNEES BY COMPANY (NO.) 124SUMMARY OF PATENTS BY COMPANY 125TABLE 92 NUMBER OF PATENTS, BY COMPANY, FOR FOUR IMAGING REAGENT MARKETSEGMENTS 125

CHAPTER 9 COMPANY PROFILES 127

ABT MOLECULAR IMAGING INC. 127

ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH 127

ACTIVE MOTIF CHROMEON GMBH 127

ACUSPHERE INC. 128

ADVANCED ACCELERATOR APPLICATIONS SA 128

ADVANCED PROTEOME THERAPEUTICS INC. 129

ADVANCED RESEARCH TECHNOLOGIES, INC. 129

AFFIBODY AB 130

TABLE 93 AFFIBODY ALLIANCES 130

AGENIX LTD. 131

ALSERES PHARMACEUTICALS INC. 131

ALZHYME PTY LTD. 132

AMAG PHARMACEUTICALS INC. 132

AMERICAN ELEMENTS 133

AMERICAN DYE SOURCE INC. 133

ANASPEC INC. 134

ANTICANCER INC. 134

APOSENSE 135

AREVA 135

ASTELLAS PHARMA INC. 136

ASTRAZENECA LTD. 136

ATREUS PHARMACEUTICALS CORPORATION 137

ATTO-TEC GMBH 137

AXXAM SPA 137

BAYER HEALTHCARE AG 138

BBI INTERNATIONAL 138

BD 139

BECKMAN COULTER INC. 140

BETAPLUS RADIOPHARMACEUTIALS LLC 140

BIOFORCE NANOSCIENCES HOLDINGS INC. 141

BIOMODA INC. 141

BIOSCAN INC. 142

BIOSEARCH TECHNOLOGIES INC. 142

BIOSCEPTRE INTERNATIONAL LIMITED 143

BIOTIUM INC. 143

BIOVISION, INC. 143

BRACCO IMAGING S.P.A. 144

CAPSULUTION PHARMA AG 145

CARDINAL HEALTH 146

CARESTREAM HEALTH INC. 146

CELLCYTE GENETICS 147

CELLPOINT LLC. 147

CHEMATECH SAS 148

CHEMICELL GMBH 148

CHINA MEDICAL TECHNOLOGIES INC. 148

CHROMOTEK GMBH 149

CISBIO BIOASSAYS 149

COVALYS BIOSCIENCES AG 150

COVIDIEN PLC 150

CYTODIAGNOSTICS 151

DAIICHI SANKYO CO. LTD. 151

DENDRITECH INC. 151

DENOVO BIOLABELS GMBH 152

EBIOSCIENCE INC. 152

ECKERT & ZIEGLER AG 152

ELI LILLY AND COMPANY 153

ERIGAL LIMITED 154

ESTECH PHARMA CO. LTD. 154

EVIDENT TECHNOLOGIES 155

EVROGEN 155

FERROPHARM GMBH 156

FLUOPTICS 156

FLUOROPHARMA INC. 157

TABLE 94 FLUORPHARMA PET IMAGING REAGENT PIPELINE 157

FUJI PHARMA CO. LTD. 158

GE HEALTHCARE 158

GENISPHERE LLC 159

GUERBET 160

IASON GMBH 160

IMAGINAB INC. 160

IMMUNOMEDICS INC. 161

INDEC BIOSYSTEMS 162

INNOPROT 162

INVISAGE INC. 162

IPSEN GROUP 163

ISO-TEX DIAGNOSTICS INC. 163

JAZZ PHARMACEUTICALS PLC 163

J.B. CHEMICALS & PHARMACEUTICALS LTD. 164

JOHNSON & JOHNSON 164

JUBILANT LIFE SCIENCES LTD. 165

KEREOS INC. 165

TABLE 95 KEREOS IMAGING REAGENTS PIPELINE 165

KPL INC. 166

LAB21 LTD 167

LABORATOIRES CYCLOPHARMA 167

LANTHEUS MEDICAL IMAGING 167

TABLE 96 LANTHEUS DIAGNOSTIC IMAGING PIPELINE 168

LIFE TECHNOLOGIES INC. 169

LUMIPHORE INC. 170

LUNA NANOWORKS 170

MARINPHARM GMBH 171

MARVAL BIOSCIENCES INC. 171

MBL INTERNATIONAL 172

MEDI RADIOPHARMA LTD 172

MELLITECH SAS 172

MOBIOTEC GMBH 173

MOLECULAR INSIGHT PHARMACEUTICALS 173

TABLE 97 MOLECULAR INSIGHT IMAGING REAGENTS PIPELINE 173

MOLECULAR TARGETING TECHNOLOGIES INC. 174

NANOAXIS LLC 175

NANOCO TECHNOLOGIES LTD. 175

NANO-H SAS 176

NANOPROBES INC. 176

NANOSCAN IMAGING LLC 177

TABLE 98 LYMPH NODE STATUS 177

NANOSPECTRA BIOSCIENCES 177

NANOSPHERE INC. 178

TABLE 99 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE 179

NAVIDEA BIOPHARMACEUTICALS 179

TABLE 100 NAVIDEA PIPELINE 180

NN-LABS LLC 181

NORDION INC. 181

NOVELOS THERAPEUTICS INC. 182

NUVIEW LIFE SCIENCES 182

OCEAN NANOTECH LLC 182

OCTREOPHARM SCIENCES GMBH 183

OXFORD CONTRAST MOLECULAR DIAGNOSTICS 183

OXONICA INC. 184

PERKINELMER INC. 184

PHARMALUCENCE INC. 186

PHILIPS HEALTHCARE 186

PHOTOCURE ASA 187

PIRAMAL HEALTHCARE LTD. 188

PRINCIPIO, INC. 188

PROMEGA CORPORATION 189

QUANTUM MATERIALS CORPORATION 189

RAPIDSCAN PHARMA SOLUTIONS INC. 190

READE ADVANCED MATERIALS 190

SIEMENS AG 190

SIRIGEN LTD. 191

SIGNALOMICS GMBH 191

SPAGO IMAGING AB 192

SOFIE BIOSCIENCES 192

TAKARA BIO INC. 193

TAEJOON PHARMA CO. LTD. 193

TARGESON INC. 194

THERAGNOSTIC TECHNOLOGIES INC. 194

THERMO FISHER SCIENTIFIC 194

TK-SIGNAL LTD. 196

TOP SRL 196

WILEX AG 196

TABLE 101 WILEX CLINICAL PRODUCT PIPELINE 197

LIST OF TABLES SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH

2017 ($ MILLIONS) 5

TABLE 1 SCOPE OF THIS REPORT 10

TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,

THROUGH 2017 ($ MILLIONS) 10

TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY END USER MARKET,

THROUGH 2017 ($ MILLIONS) 11

TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 12

TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS 14

TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPANIES 15

TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES 17

TABLE 8 IN-VIVO IMAGING MODALITIES 18

TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES 19

TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING 21

TABLE 11 KEY TECHNOLOGY DRIVERS FOR IN-VIVO IMAGING REAGENTS 22

TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS 24

TABLE 13 FLUORESCENT DYES AND PROBES 25

TABLE 14 GENERAL ADVANTAGES OF FLUORESCENCE LABELS 26

TABLE 15 FLUORESCENT DYE PERFORMANCE CRITERIA 27

TABLE 16 TYPES OF FLUORESCENT PROTEINS 28

TABLE 17 PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES 29

TABLE 18 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS 31

TABLE 19 FLUORESCENT PROTEINS VERSUS DYES 32

TABLE 20 TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS 32

TABLE 21 CLASSIFICATION OF IMAGING SUPERMOLECULES 33

TABLE 22 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT

PROTEINS 34

TABLE 23 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS 37

TABLE 24 MICROBUBBLE ULTRASOUND IMAGING AGENTS 40

TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS 42

TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES 46

TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS 47

TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS 48

TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS 50

TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND

MEDICAL INDUSTRIES 51

TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT 52

TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS 52

TABLE 33 R&D TOOLS IMAGING REAGENTS 53

TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS 54

TABLE 35 IMAGING APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 55

TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES 58

TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING 59

TABLE 38 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS 60

TABLE 39 DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS 61

TABLE 40 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING 63

TABLE 41 BIOLOGIC IMAGING REAGENT STRATEGIC ALLIANCES, 2010-2012 67

TABLE 42 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2010–2012 71

TABLE 43 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES 73

TABLE 44 FLUORESCENT IMAGING REAGENTS COMPETITORS 74

TABLE 45 QUANTUM DOT COMPETITORS 75

TABLE 46 CONTRAST AGENTS KEY COMPETITORS 77

TABLE 47 IMAGING RADIOPHARMACEUTICALS COMPANIES 77

TABLE 48 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES 79

TABLE 49 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING REAGENT COMPETITORS 81

TABLE 50 CARDIAC IMAGING REAGENT COMPETITIVE SPACE 82

TABLE 51 PROSTATE CANCER IMAGING AGENT COMPETITION 84

TABLE 52 ALZHEIMER'S DISEASE PET IMAGING AGENT COMPETITIVE SPACE 85

TABLE 53 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 88

TABLE 54 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY APPLICATION, THROUGH

2017 ($ MILLIONS) 90

TABLE 55 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,

THROUGH 2017 ($ MILLIONS) 91

TABLE 56 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS MARKET, BY END USE,

THROUGH 2017 ($ MILLIONS) 92

TABLE 57 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET,

THROUGH 2017 ($ MILLIONS) 92

TABLE 58 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY MODALITY, THROUGH 2017

($ MILLIONS) 93

TABLE 59 GLOBAL VALUE OF CONTRAST REAGENTS MARKET, BY MODALITY, THROUGH 2017

($ MILLIONS) 94

TABLE 60 GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE, THROUGH 2017 ($

MILLIONS) 95

TABLE 61 GLOBAL VALUE OF GD-CHELATE MRI REAGENTS BY PRODUCT, THROUGH 2017 ($

MILLIONS) 96

TABLE 62 GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, THROUGH 2017 ($

MILLIONS) 98

TABLE 63 GLOBAL SALES OF MRI CONTRAST REAGENTS BY PROCEDURE, THROUGH 2017 ($

MILLIONS) 99

TABLE 64 GLOBAL VALUE OF MICROBUBBLE ULTRASOUND REAGENTS MARKET, BY TYPE,

THROUGH 2017 ($ MILLIONS) 99

TABLE 65 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY TYPE, THROUGH 2017 ($

MILLIONS) 101

TABLE 66 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY INDICATION, THROUGH 2017

($ MILLIONS) 102

TABLE 67 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

SCANNER TYPE, THROUGH 2017 ($ MILLIONS) 102

TABLE 68 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

ISOTOPE, THROUGH 2017 ($ MILLIONS) 103

TABLE 69 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

INDICATION, THROUGH 2017 ($ MILLIONS) 104

TABLE 70 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY

TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 105

TABLE 71 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH

2017 ($ MILLIONS) 106

TABLE 72 HALF LIFE OF COMMON PET AND SPECT ISOTOPES 107

TABLE 73 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY INDICATION,

THROUGH 2017 ($ MILLIONS) 107

TABLE 74 SENTINEL NODE DETECTION RADIOPHARMACEUTICALS PRODUCERS 108

TABLE 75 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY TECHNOLOGY,

THROUGH 2017 ($ MILLIONS) 109

TABLE 76 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH

2017 ($ MILLIONS) 110

TABLE 77 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY INDICATION, THROUGH

2017 ($ MILLIONS) 110

TABLE 78 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY TECHNOLOGY,

THROUGH 2017 ($ MILLIONS) 112

TABLE 79 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY

APPLICATION, THROUGH 2017 ($ MILLIONS) 112

TABLE 80 GLOBAL VALUE OF IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS

MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 113

TABLE 81 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING

REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 114

TABLE 82 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING

REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 115

TABLE 83 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT

IMAGING REAGENTS MARKET BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 116

TABLE 84 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE,

THROUGH 2017 ($ MILLIONS) 116

TABLE 85 GLOBAL VALUE OF IN-VITRO OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH

2017 ($ MILLIONS) 117

TABLE 86 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH

2017 ($ MILLIONS) 118

TABLE 87 NUMBER OF PATENTS BY TECHNOLOGY, 2001-2011 121

TABLE 88 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY (NO.) 122

TABLE 89 FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY (NO.) 123

TABLE 90 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY (NO.) 123

TABLE 91 GOLD NANOPARTICLE PATENT ASSIGNEES BY COMPANY (NO.) 124

TABLE 92 NUMBER OF PATENTS, BY COMPANY, FOR FOUR IMAGING REAGENT MARKET

SEGMENTS 125

TABLE 93 AFFIBODY ALLIANCES 130

TABLE 94 FLUORPHARMA PET IMAGING REAGENT PIPELINE 157

TABLE 95 KEREOS IMAGING REAGENTS PIPELINE 165

TABLE 96 LANTHEUS DIAGNOSTIC IMAGING PIPELINE 168

TABLE 97 MOLECULAR INSIGHT IMAGING REAGENTS PIPELINE 173

TABLE 98 LYMPH NODE STATUS 177

TABLE 99 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE 179

TABLE 100 NAVIDEA PIPELINE 180

TABLE 101 WILEX CLINICAL PRODUCT PIPELINE 197

LIST OF FIGURES SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH

2017 ($ MILLIONS) 5

FIGURE 1 QUANTUM DOT SPECTRA (INTENSITY) 35

FIGURE 2 FLUORESCENT DYE SPECTRA 35

FIGURE 3 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 41

FIGURE 4 ESTIMATED MANUFACTURING COSTS OF IMAGING REAGENTS CLASSES ($/GRAM) 44

FIGURE 5 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT 57

To order this report:Medical_Imaging Industry: Biologic Imaging Reagents: Technologies and Global Markets

CONTACT
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.